Upcoming events – Ascendis and Lilly hope for growth with pivotal data

Welcome to your weekly digest of approaching regulatory and clinical readouts. The failure of Versartis’s long-acting human growth hormone (hGH) somavartan in 2017 prompted the share price of its rival Ascendis Pharma to rise 44%, and the stock has nearly doubled since as investors await the first-quarter readout of phase III trials in paediatric growth hormone deficiency.